Skip to main content

Helping you deliver the highest quality care to your male patients

Many infections can affect men in very different ways than they affect women. We provide a wide range of tests that align with guidelines from leading organizations that are specific to your male patients.
doctor writing notes


The insights you need to provide the best care for your patients

According to the annual Sexually Transmitted Disease Surveillance Report, STDs increased for the fifth consecutive year—with nearly 2.5 million combined cases of chlamydia, gonorrhea, and syphilis.1

In the past few years, reported cases of chlamydia, gonorrhea, and syphilis have increased, especially among men:2

  • 26.8% increase in reported cases of chlamydia2
  • 62.2% increase in reported cases of gonorrhea2
  • 74.2% increase in reported cases of syphilis2

Genital herpes is common in the United States. More than 1 out of every 6 people aged 14 to 49 years have genital herpes.3

Genital herpes is caused by 2 types of viruses: herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2). Oral herpes is usually caused by HSV-1 and can result in cold sores or fever blisters on or around the mouth. Oral herpes caused by HSV-1 can be spread from the mouth to the genitals through oral sex.

Human immunodeficiency virus (HIV) is the virus that causes AIDS. When a person becomes infected with HIV, the virus attacks and weakens the immune system. In the United States, people who have syphilis, gonorrhea, and herpes often also have HIV, or are more likely to get HIV in the future.4

In 2018, men accounted for 30,691 (81%) of the 37,968 new HIV diagnoses in the United States and dependent areas. Most (86%) new diagnoses among men were attributed to gay, bisexual, and other men who have sex with men.5

Today’s guidelines say that everyone between the ages of 13 and 64 should get tested for HIV6

In order to increase detection of pharyngeal or rectal infections, strategies must evolve to include more extra-genital screening for higher-risk patients, including: 7

  • Men who have sex with men
  • People with more than 1 sexual partner
  • Transgender people who have sex with men
  • People who have recently had an STI
  • People who use injection drugs
  • People who have sex with a partner who has HIV

Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. 79 million Americans, most in their late teens and early 20s, are infected with HPV.8

Most men who get HPV never develop symptoms and the infection usually goes away completely by itself. However, if HPV does not go away, it can cause genital warts or certain kinds of cancer. Consider testing your male patients who exhibit anything unusual such as warts, or unusual growths, lumps, or sores on the penis, scrotum, anus, mouth, or throat.

Hepatitis C virus (HCV) remains a silent epidemic in the United States, where an estimated 2.4 million people are living with chronic hepatitis C.9

According to the Centers for Disease Control and Prevention10,11:

  • New hepatitis C cases are 4 times as high as they were 10 years ago
  • The annual rate of reported acute hepatitis C tripled from 2009 to 2018
  • Rates of acute hepatitis C among people of reproductive age are increasing

Guidelines recommend HCV screening for12,13:

  • All adults aged 18 years and older
  • People with recognized conditions or exposures
  • People with ongoing risk factors, including persons who inject drugs (PWID) (routine periodic testing)
  • Any person who requests hepatitis C testing

Mycoplasma genitalium is increasingly recognized as an important sexually transmitted infection (STI), with an estimated prevalence of 1% to 3% in the general population.14

High-risk populations may have a much higher prevalence (up to 24% among men and 16% among women), comparable to that of chlamydia.14

  • Responsible for 30% of persistent or recurrent urethritis in men15
  • Causes up to 20% of nonchlamydial nongonococcal infections in men16
  • Infected patients are 2 times more likely to acquire HIV17

Mycoplasma genitalium infections may go unrecognized, either because infected individuals are asymptomatic or the symptoms are the same as those associated with other infections of the urogenital tract (eg, chlamydia, gonorrhea, or trichomoniasis). Accurate identification of a patient’s Mycoplasma genitalium infection status is critical for effective patient treatment for reproductive disorders.

Gram stain and culture are not clinically feasible methods of detection for Mycoplasma genitalium due to the pathogen’s lack of cell wall18 and fastidious nature.15 NAATs are preferred for detecting Mycoplasma genitalium because this pathogen cannot be visualized under a microscope and is prohibitively difficult to culture.16
 

A comprehensive test menu for your male patients

Laboratory Screening Test name Test code CPT codea
Chlamydia Chlamydia trachomatis RNA, TMA, Urogenital 11361 87491
Chlamydia trachomatis RNA, TMA, Rectal 16505 87491
Chlamydia trachomatis RNA, TMA, Throat 70048 87491
Gonorrhea Neisseria gonorrhoeae RNA, TMA, Urogenital 11362 87591
Neisseria gonorrhoeae RNA, TMA, Rectal 16504 87591
Neisseria gonorrhoeae RNA, TMA, Throat 70049 87591
Chlamydia and Gonorrhea Chlamydia/Neisseria gonorrhoeae RNA, TMA, Urogenital 11363 87491, 87591
Chlamydia/Neisseria gonorrhoeae RNA, TMA, Rectal 16506 87491, 87591
Chlamydia/Neisseria gonorrhoeae RNA, TMA, Throat 70051 87491, 87591
Trichomonas vaginalis Trichomonas vaginalis RNA, Qualitative, TMA, Males 90801 87661
Chlamydia, Gonorrhea and Trichomonas vaginalis SureSwab®, CT/NG, T vaginalis 16492 87491, 87591, 87661
Mycoplasma genitalium Mycoplasma genitalium, rRNA, TMA 91475 87563
Herpes simplex virus 1/2 for lesions SureSwab®, Herpes Simplex Virus, Type 1 and 2 mRNA,TMA 90570 87529 (x2)
Herpes simplex virus 1/2 serology Herpes Simplex Virus 1 and 2 (IgG), with Reflex to HSV-2 Inhibition 17169 86695, 86696
Male Urethritis Sexually-Transmitted Infections (STIs) Male Urethritis Panel 36964 87491, 87591, 87661, 87563
Male Urethritis Expanded Sexually-Transmitted Infections (STIs) Male Urethritis Panel, Expanded 38288 87491, 87591, 87661, 87798 (x2), 87563
Genital Lesion Sexually-Transmitted Infections (STIs) Genital Lesion Panel 38286 87529 (x2), 87798
Syphilis lesion Treponema pallidum DNA, Qualitative Real-Time PCR 16595 87798
Syphilis serology RPR (Diagnosis) with Reflex to Titer and Confirmatory Testing 36126 86592
Hepatitis C Hepatitis C Antibody with Reflex to HCV, RNA, Quantitative, Real-Time PCR 8472 86803
HPV HPV mRNA E6/E7, Rectal 91932 87624
HPV mRNA E6/E7, Rectal with Reflex to Genotypes, 16, 18/45 92810 87624
HPV Genotypes 16, 18/45, Anal-Rectal 92807 87625
Cytology, non-gynecological Cytology, Non-Gynecological, Fluid, Washings, Brushings or FNA 10676 88104, 88108, 88112, 88160, 88161, 88162, 87207, 88172, 88173, 88305

Components of panels can be ordered separately.

Test codes may vary by location. Please contact your local laboratory for more information.

a The CPT® codes provided are based on American Medical Association guidelines an are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

 

​References:

  1. CDC. 2018 STD surveillance report. Updated October 8, 2019. Accessed November 20, 2020. https://www.cdc.gov/nchhstp/newsroom/2019/2018-STD-surveillance-report.html
  2. CDC. Sexually transmitted disease surveillance 2016. Published September 2017. Accessed November 20, 2020. https://www.cdc.gov/std/stats16/CDC_2016_STDS_Report-for508WebSep21_2017_1644.pdf
  3. CDC. Genital herpes – CDC fact sheet. Updated August 28, 2017. Accessed November 20, 2020. https://www.cdc.gov/std/herpes/stdfact-herpes.htm
  4. CDC. STDs and HIV – CDC fact sheet. Updated March 30, 2020. Accessed November 20, 2020. https://www.cdc.gov/std/hiv/stdfact-std-hiv.htm
  5. CDC. HIV and men. Updated November 5, 2020. Accessed November 20, 2020. https://www.cdc.gov/hiv/group/gender/men/
  6. CDC. HIV testing. Updated June 9, 2020. Accessed November 20, 2020. https://www.cdc.gov/hiv/testing/index.html
  7. CDC. Clinical prevention guidance. Updated June 4, 2015. Accessed October 17, 2017. https://www.cdc.gov/std/tg2015/clinical.htm
  8. CDC. Genital HPV infection – fact sheet. Updated August 20, 2019. Accessed November 20, 2020. https://www.cdc.gov/std/hpv/stdfact-hpv.htm
  9. Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016. Hepatology. 2019;69(3):1020-1031. doi:10.1002/hep.30297
  10. CDC. Dramatic increases in hepatitis C. Updated April 9, 2020. Accessed May 7, 2020. https://www.cdc.gov/hepatitis/hcv/vitalsigns/index.html
  11. Ryerson AB, Schillie S, Barker LK, et al. Vital signs: newly reported acute and chronic hepatitis c cases—United States, 2009-2018. MMWR Morb Mortal Wkly Rep. 2020;69(14):399-404. doi:10.15585/mmwr.mm6914a2
  12. CDC. CDC recommendations for hepatitis C screening among adults—United States, 2020. Updated April 10, 2020. Accessed May 6, 2020. https://www.cdc.gov/mmwr/volumes/69/rr/rr6902a1.htm
  13. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2020;323(10):970-975. doi:10.1001/jama.2020.1123
  14. Aptima® Mycoplasma genitalium Assay [package insert]. Hologic Inc.; 2019.
  15. CDC. Emerging issues. Updated June 4, 2015. Accessed November 20, 2019. https://www.cdc.gov/std/tg2015/emerging.htm
  16. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1-137.
  17. Napierala Mavedzenge S, Weiss HA. Association of Mycoplasma genitalium and HIV infection: a systematic review and meta-analysis. AIDS. 2009;23(5):611-620. doi:10.1097/QAD.0b013e328323da3e
  18. Manhart LE, Broad JM, Golden MR. Mycoplasma genitalium: should we treat and how? Clin Infect Dis. 2011;53(S3):S129-S142. doi:10.1093/cid/cir702

Universal screening with opt-out for CT/NG screening

The latest CDC Guidelines recommended considering universal screening with opt-out as part of routine care for all female patients ages 15 - 24.*
*Workowski KA, et al. MMWR. doi:10.15585/mmwr.rr7004a1

Click to learn more

Assessing high-risk patients

With rates of sexually transmitted infections (STIs) on the rise, assessing women who may be high-risk is more important than ever.

Click to learn more

STI webinar series

Listen to the experts as they discuss STI testing beyond Chlamydia trachomatis and Neisseria gonorrheae.

Click to learn more

Contact us

Contact us to receive additional information on our lab tests, services, and coverage

Contact us